Open Label, Single Arm, Phase I/II Study of CADI-05 in Patients With Advanced Stage III or Stage IV Melanoma

NCT00675727 Phase 1/Phase 2 TERMINATED

This study examines the safety of treating patients with advanced stage melanoma with the vaccine CADI-05. In addition, preliminary data regarding the clinical response and immune response will be collected.

Details

Lead sponsor	Cadila Pharnmaceuticals
Phase	Phase 1/Phase 2
Status	TERMINATED
Enrolment	20
Start date	2006-12

Conditions

• Stage III or Stage IV Melanoma

Interventions

• CADI-05

Primary outcomes

• Recording of any clinical adverse reactions at anytime during the study for assessment of safety. — 6-24 months

Countries

United States